Board
Screen
Heat
Cal
Watch
News
Blog
TV
Home
/
AVTX
Home
/
AVTX

NASDAQ
$7.07
$7.07

Overview

Price performance
Low
$6.79
High
$7.59
After hours. Last updated: Nov 4, 2026, 9:00 PM UTC
$
7.07
-0.18 (-2.48%)
Average, 50 days
$14.28
$15.95
Open
$7.49
Previous close
$7.25
52-week high
$24.27
May 7, 2026 (7 months ago)
52-week low
$6.53
Oct 23, 2026 (13 days ago)
8.27%

Valuation & Estimates

Earnings

Financials

Insider Trading

Peer Analysis

Insights & Activity

Market Cap
379.16M
Volume
1 378 594
Total Return (3M)
-61.85%
Total Return (1Y)
-56.06%
—
Sector
Healthcare
Links
Tags
Healthcare
Biotechnology
NASDAQ
US
Website
avalotx.com
About
Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit LIGHT. This drug is currently undergoing Phase II clinical trials for non-eosinophilic asthma and inflammatory bowel diseases, specifically moderate to severe Crohn's disease and ulcerative colitis. Furthermore, AVTX-002 is also being investigated in Phase III for its potential to treat acute respiratory distress syndrome caused by COVID-19. The company is also advancing AVTX-007, a fully human monoclonal antibody targeting IL-18, which is progressing through Phase I clinical studies for Still's disease, encompassing both adult-onset Still's disease and systemic juvenile idiopathic arthritis. Avalo's late-stage pipeline includes two products addressing rare genetic conditions, both in Phase III clinical trials: AVTX-801, a D-galactose substrate replacement therapy for phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, an L-fucose substrate replacement therapy intended for LADII, medically referred to as SLC35C1-CDG. Established in 2011, the corporation initially operated as Cerecor Inc. before rebranding as Avalo Therapeutics, Inc. in August 2021. Its main operations are situated in Rockville, Maryland.

Frequently asked questions

AVTX · Avalo Therapeutics, Inc.

01What is Avalo Therapeutics, Inc. stock price today?

The current price of AVTX is $7.07 — it has decreased by 2.48% since the previous close. Data as of Nov 4, 2026.

02Is Avalo Therapeutics, Inc. stock price growing?

AVTX is down 4.20% over the past week, down 52.84% over the past month and down 56.06% over the past year. The price is below its 200-day moving average of $15.95.

03What is Avalo Therapeutics, Inc. market cap?

Avalo Therapeutics, Inc. has a market capitalization of $379.16M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.

04How volatile is AVTX stock?

In the latest trading session AVTX moved between $6.79 and $7.59, a range of 11.27% of its current price.

05What are AVTX stock 52-week high and low?

Over the past 52 weeks AVTX has traded between $6.53 and $24.27. The current price is 70.87% below its 52-week high.

Figures as of Nov 4, 2026. This information is provided for general purposes only and is not investment advice.